Acadia Pharmaceuticals Inc. Receives Positive EMA Review for DAYBU (Trofinetide)

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive review of DAYBU (trofinetide). The review follows a re‑check procedure and supports a potential market authorization in the European Union for the treatment of neurobehavioural symptoms of Rett syndrome in both adults and children aged five and older.

The positive CHMP opinion represents a significant regulatory milestone for Acadia. If the European Commission approves the drug, DAYBU would become the first licensed therapy in the EU for Rett syndrome, a rare genetic neurological and developmental disorder.

Market Impact

The announcement triggered a sharp rally in Acadia’s shares. The stock rose more than 10 % in pre‑market trading on June 26, 2026, and continued to climb throughout the day. At the close of the session on June 25, Acadia’s share price stood at $25.32, a level comfortably below its 52‑week high of $28.35 (recorded on December 22, 2025) and above its 52‑week low of $19.69 (October 12, 2025). The company’s market capitalization is approximately $4.06 billion.

Company Context

Acadia Pharmaceuticals is a biotechnology firm headquartered in San Diego that develops small‑molecule drugs for central nervous system disorders, including Parkinson’s disease, schizophrenia, neuropathic pain, and glaucoma. The company’s focus on neurological conditions aligns with the therapeutic profile of DAYBU, which targets Rett syndrome’s neurobehavioural manifestations.

Forward‑Looking Statements

The company’s statement noted that the final approval decision by the European Commission is expected in the coming months. The timing of the Commission’s vote will determine the exact launch date for DAYBU in the EU market.

Summary

  • Positive CHMP review for DAYBU, potential first EU approval for Rett syndrome treatment.
  • Share price rally following the announcement.
  • Current share price: $25.32; 52‑week range: $19.69 – $28.35.
  • Market capitalization: $4.06 billion.

The development positions Acadia Pharmaceuticals as a key player in the neurobehavioural therapeutics market and may influence its valuation trajectory in the near term.